[ad_1]
FILE PHOTO: A sign is visible on an AstraZeneca site in Macclesfield, in central England, on May 19, 2014. REUTERS / Phil Noble / File Photo
(Reuters) – AstraZeneca Plc and Japan's Daiichi Sankyo Co Ltd have signed a potential multi-billion dollar partnership to develop and sell Daiichi's anti-cancer drug trastuzumab deruxtecan.
As part of this deal, AstraZeneca will pay Daiichi up to $ 6.9 billion, including an upfront payment of $ 1.35 billion. The two companies will share the costs of drug development and commercialization worldwide, with Daiichi retaining exclusive rights in Japan.
The news sent Daiichi shares up 16%, its daily limit on Friday morning in Tokyo.
Trastuzumab deruxtecan "could potentially redefine the treatment of bad cancer as the first treatment of tumors with low HER2 expression," said AstraZeneca CEO Pascal Soriot, in a statement, referring to a type of cancer of the liver. bad fed by a protein called HER2.
Report by Sam Nussey in Tokyo and Bhargav Acharya in Bengaluru; Edited by Sandra Maler and Muralikumar Anantharaman
Source link
